OBJECTIVE:Children with Pervasive Developmental Disorders (PDDs) have social interaction deficits, delayed communication, and repetitive behaviors as well as impairments in adaptive functioning. Many children actually show a decline in adaptive skills compared with age mates over time. METHOD: This 24-week, three-site, controlled clinical trial randomized 124 children (4 through 13 years of age) with PDDs and serious behavioral problems to medication alone (MED; n = 49; risperidone0.5 to 3.5 mg/day; if ineffective, switch toaripiprazole was permitted) or a combination of medication plus parent training (PT) (COMB; n = 75). Parents of children in COMB received an average of 11.4 PT sessions. Standard scores and Age-Equivalent scores on Vineland Adaptive Behavior Scales were the outcome measures of primary interest. RESULTS:Seventeen subjects did not have a post-randomization Vineland assessment. Thus, we used a mixed model with outcome conditioned on the baseline Vineland scores. Both groups showed improvement over the 24-week trial on all Vineland domains. Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively). On Age Equivalent scores, Socialization and Communication domains showed greater improvement in COMB versus MED (p = .03 and 0.05, and effect sizes = 0.33 and 0.14, respectively). Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02). After controlling for IQ, this difference was no longer significant. CONCLUSION: Reduction of serious maladaptive behavior promotes improvement in adaptive behavior. Medication plus PT shows modest additional benefit over medication alone. Clinical trial registration information-RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://www.clinicaltrials.gov; NCT00080145.
RCT Entities:
OBJECTIVE:Children with Pervasive Developmental Disorders (PDDs) have social interaction deficits, delayed communication, and repetitive behaviors as well as impairments in adaptive functioning. Many children actually show a decline in adaptive skills compared with age mates over time. METHOD: This 24-week, three-site, controlled clinical trial randomized 124 children (4 through 13 years of age) with PDDs and serious behavioral problems to medication alone (MED; n = 49; risperidone 0.5 to 3.5 mg/day; if ineffective, switch to aripiprazole was permitted) or a combination of medication plus parent training (PT) (COMB; n = 75). Parents of children in COMB received an average of 11.4 PT sessions. Standard scores and Age-Equivalent scores on Vineland Adaptive Behavior Scales were the outcome measures of primary interest. RESULTS: Seventeen subjects did not have a post-randomization Vineland assessment. Thus, we used a mixed model with outcome conditioned on the baseline Vineland scores. Both groups showed improvement over the 24-week trial on all Vineland domains. Compared with MED, Vineland Socialization and Adaptive Composite Standard scores showed greater improvement in the COMB group (p = .01 and .05, and effect sizes = 0.35 and 0.22, respectively). On Age Equivalent scores, Socialization and Communication domains showed greater improvement in COMB versus MED (p = .03 and 0.05, and effect sizes = 0.33 and 0.14, respectively). Using logistic regression, children in the COMB group were twice as likely to make at least 6 months' gain (equal to the passage of time) in the Vineland Communication Age Equivalent score compared with MED (p = .02). After controlling for IQ, this difference was no longer significant. CONCLUSION: Reduction of serious maladaptive behavior promotes improvement in adaptive behavior. Medication plus PT shows modest additional benefit over medication alone. Clinical trial registration information-RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://www.clinicaltrials.gov; NCT00080145.
Authors: A S Carter; F R Volkmar; S S Sparrow; J J Wang; C Lord; G Dawson; E Fombonne; K Loveland; G Mesibov; E Schopler Journal: J Autism Dev Disord Date: 1998-08
Authors: Michael G Aman; Christopher J McDougle; Lawrence Scahill; Benjamin Handen; L Eugene Arnold; Cynthia Johnson; Kimberly A Stigler; Karen Bearss; Eric Butter; Naomi B Swiezy; Denis D Sukhodolsky; Yaser Ramadan; Stacie L Pozdol; Roumen Nikolov; Luc Lecavalier; Arlene E Kohn; Kathleen Koenig; Jill A Hollway; Patricia Korzekwa; Allison Gavaletz; James A Mulick; Kristy L Hall; James Dziura; Louise Ritz; Stacie Trollinger; Sunkyung Yu; Benedetto Vitiello; Ann Wagner Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-12 Impact factor: 8.829
Authors: James T McCracken; James McGough; Bhavik Shah; Pegeen Cronin; Daniel Hong; Michael G Aman; L Eugene Arnold; Ronald Lindsay; Patricia Nash; Jill Hollway; Christopher J McDougle; David Posey; Naomi Swiezy; Arlene Kohn; Lawrence Scahill; Andres Martin; Kathleen Koenig; Fred Volkmar; Deirdre Carroll; Allison Lancor; Elaine Tierney; Jaswinder Ghuman; Nilda M Gonzalez; Marco Grados; Benedetto Vitiello; Louise Ritz; Mark Davies; James Robinson; Don McMahon Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos Journal: Antioxid Redox Signal Date: 2019-02-01 Impact factor: 8.401
Authors: Kristen K Criado; William G Sharp; Courtney E McCracken; Oana De Vinck-Baroody; Liansai Dong; Michael G Aman; Christopher J McDougle; James T McCracken; L Eugene Arnold; Carol Weitzman; John M Leventhal; Benedetto Vitiello; Lawrence Scahill Journal: Autism Date: 2017-03-22
Authors: Lawrence Scahill; Sangchoon Jeon; Susan J Boorin; Christopher J McDougle; Michael G Aman; James Dziura; James T McCracken; Sonia Caprio; L Eugene Arnold; Ginger Nicol; Yanhong Deng; Saankari A Challa; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-03-07 Impact factor: 8.829